V8 Peptides — Engineered Performance
Research Library
IGF-1 LR3 vs Standard IGF-1: Binding Proteins in Culture
IGF-1 LR3Comparison

IGF-1 LR3 vs Standard IGF-1: Binding Proteins in Culture

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does IGF-1 LR3 differ from standard (native) IGF-1 in the lab? Native IGF-1 is a 70-residue single-chain peptide with three disulfide bonds and a sequence closely related to proinsulin. IGF-1 LR3 is an 83-residue analog: Glu3 is replaced by Arg and a 13-residue extension is added at the N-terminus. Those changes sharply reduce binding to IGF-binding proteins (IGFBPs), so in cultures that contain IGFBPs the analog is reported to behave as a more potent and more consistent agonist than native IGF-1. In defined media that contain few IGFBPs the gap narrows. Supplied for laboratory research use only.

Native IGF-1 is the reference molecule that every analog is measured against, so a clear picture of it makes the analog easier to understand. This article follows the molecule rather than the decision: what native IGF-1 is, how it behaves in a culture dish, why an IGFBP-poor analog was designed, and what to check when moving from one to the other. For a choice between two engineered analogs, see IGF-1 LR3 vs des(1-3) IGF-1. The V8 IGF-1 LR3 product page describes the analog supplied, and the research overview gives the broader background.

Native IGF-1: sequence and structure

The amino acid sequence of human IGF-1 was reported by Rinderknecht and Humbel in 1978, who described a single chain of 70 residues with a striking structural homology to proinsulin (Rinderknecht 1978). In practice that means the molecule has A and B regions that resemble the insulin chains, joined by a short connecting region, with an extra C-terminal extension. Three disulfide bonds hold the fold together, and the native N-terminal tripeptide Gly-Pro-Glu sits at the start of the chain. That same N-terminus is the site where the engineered analogs differ.

The homology to insulin explains why the IGF and insulin systems overlap. Signaling by the insulin receptor and the type 1 IGF receptor shares major downstream pathways, and reviews describe supporting proteins and new players that fine-tune the output (Siddle 2011). For a bench scientist the lesson is that a response to IGF-1 in a cell line may involve more than one receptor, which is a reason to include receptor-blocking controls when attributing a result.

What happens to native IGF-1 in a culture dish

Culture media are not inert. Serum contains IGFBPs, and many cell types make their own. These proteins bind IGF-1 with high affinity; reviews note that they can inhibit IGF action by sequestering the ligand away from the receptor, and that proteolysis of the binding protein can release IGF again (Firth and Baxter 2002). Matrix and cell-surface association adds another layer: in some situations an IGFBP bound near the cell can raise the local IGF concentration. The same reviews stress that effects differ by IGFBP type and by cell context (Baxter 2000).

So the nominal concentration of native IGF-1 added to a dish is not the concentration the receptor sees. Part of the ligand is bound, part is free, and the split can change over hours as cells secrete more binder or cleave existing binder. Two labs adding the same mass of native IGF-1 to different media or cell densities can report different potencies for reasons that have nothing to do with the peptide.

Factor in the dishEffect on native IGF-1Why an IGFBP-poor analog changes the picture
Serum in the mediumBrings IGFBPs that bind the ligandAnalog is less captured by those proteins
Cells that secrete IGFBPsBinder accumulates over the assayLess drift in effective concentration
Protease activityCleaves IGFBPs, releasing IGFSmaller contribution to the signal
Matrix or cell-surface bindingMay raise local concentrationLess concentration effect from this route
Defined serum-free mediumFew binders presentBoth forms behave more alike

The design logic of IGF-1 LR3

The engineered analogs all change the N-terminal end of the molecule, and the design goal was lower binder capture. In the work that introduced the Long analogues, Francis and colleagues made fusion peptides in which an 11-residue porcine growth hormone sequence plus Val-Asn precede IGF-1, and in the Long [Arg3] version Glu3 is replaced by Arg (Francis 1992). Earlier structural-analog work had shown that IGF-1 variants with reduced affinity for serum binding proteins could be built (Bayne 1988), and a truncated form, destripeptide IGF-1, was shown by Ballard and colleagues to be about seven times more potent than IGF-1 in a protein-synthesis bioassay without improved competition for binding to the cells (Ballard 1987).

The title of the Francis paper states the conclusion of that program directly: the analogues indicate the relative importance of IGF-binding protein and receptor binding for enhancing growth. In other words, comparing native IGF-1 with a binder-poor analog is a way of measuring how much IGFBPs were restraining the native signal. That is the main reason to run both in one experiment.

FeatureNative IGF-1IGF-1 LR3
Residues7083
Position 3GluArg
N-terminusGly-Pro-Glu start13-residue extension
Approximate massabout 7.6 kDaabout 9.1 kDa (product page)
IGFBP bindingHigh affinitySharply reduced
Supplied as listed hereNot listedLyophilized powder, 1 mg, ≥98% HPLC purity

Planning a native-versus-LR3 comparison

A clean comparison needs matched molar concentrations. The analog is heavier, so equal masses give fewer moles of LR3. Use n = m / MW for moles and C = n / V for concentration, then dilute with C1V1 = C2V2. The reconstitution calculator handles the vial arithmetic and reconstitution calculator guide explains the inputs. Prepare both peptides the same way, on the same day, in the same diluent, and aliquot them identically.

Pick a readout with a defined mechanism: a phosphorylation endpoint on a short time scale reports receptor activation, while proliferation over days integrates receptor signaling with IGFBP turnover. Reporting both can show whether differences between the two peptides emerge early, which would suggest receptor-level effects, or late, which would suggest IGFBP dynamics. Add a vehicle control, a receptor-blocking arm, and where practical a condition in which IGFBPs are removed or neutralized, so that the contribution of binders is tested rather than assumed.

Handling differences that matter

Both peptides are basic proteins that adsorb to surfaces, and that loss is proportionally larger in dilute solutions. Low-binding tubes and tips, few transfers and preparation of dilutions immediately before use limit the effect; the general case for choosing plasticware carefully when working with peptides has been documented (Goebel-Stengel 2011). Neither analog should be exposed to reducing agents, which would break the disulfide bonds. Freeze–thaw cycles concentrate the protein and create ice interfaces that favor aggregation, so divide stock into single-use portions.

The product page states storage at 2–8 °C with −20 °C for long-term holding, protection from heat, moisture and light, and a sealed clear glass research vial, which gives no light protection on its own. Let the vial reach room temperature before opening, run the diluent down the wall, and swirl rather than shake. The lyophilized peptide reconstitution guide and how long reconstituted peptides last cover the general rules. Purity of ≥98% by HPLC is stated on the product page; certificates appear in the COA library where published, and IGF-1 LR3 purity testing explains why folding and identity deserve their own checks.

Interpreting results across the two forms

If the analog gives a larger or steadier response than native IGF-1, the straightforward reading is that IGFBPs were limiting the native signal in that system. If the two give the same response, binders were not material under those conditions. If the analog gives a smaller response, check peptide quality and folding first, then consider whether the cells respond to a receptor-binding difference rather than a binder difference. Each outcome is informative, and none of them is a statement about the cells in any other medium.

Keep the language in the methods precise. Write “IGF-1 LR3 at 10 nM in serum-free medium” rather than “IGF-1 at an effective concentration,” because the analog is not the native hormone. Cite the analog design papers when describing it, record the lot, and keep the vial handling log. More background is available in IGF-1 LR3 explained, and the full catalog is on the shop page. All material is for laboratory research use only; not for human or animal consumption.

Frequently asked questions

What is standard IGF-1?

Native human IGF-1 is a 70-residue single-chain peptide with three disulfide bonds and a sequence related to proinsulin, first reported in 1978. It is the reference against which engineered analogs such as IGF-1 LR3 are compared.

How many amino acids does IGF-1 LR3 have?

83. It is native IGF-1 with Glu3 replaced by Arg and a 13-residue N-terminal extension added, which gives it a mass of roughly 9.1 kDa according to the product page.

Why is IGF-1 LR3 used in serum-free media?

Because its reduced binding to IGFBPs means less of it is captured by binders that cells secrete, so its effective concentration is more predictable than that of native IGF-1.

Do IGF-binding proteins always inhibit IGF action?

No. Reviews describe inhibition by sequestration, but also situations where cell or matrix association of an IGFBP concentrates IGF near the receptor. The effect depends on the IGFBP type and the cellular context.

Is more potent the same as higher receptor affinity?

Not necessarily. In an early comparison, destripeptide IGF-1 was about seven times more potent than IGF-1 in a bioassay without being better at competing for binding to the cells, which suggests reduced interference rather than tighter binding.

How do I match native IGF-1 and LR3 in an experiment?

Convert both to moles using their own molecular weights (n = m / MW), then prepare solutions at the same molar concentration. Do not match by mass, because the analog is heavier.

What controls help interpret a native-versus-LR3 result?

A vehicle control, a receptor-blocking arm to attribute the signal to the right receptor, and where possible a condition in which IGFBPs are removed or neutralized.

How should IGF-1 LR3 be stored?

Per the product page: refrigerate at 2–8 °C, hold at −20 °C for long-term storage, and protect from heat, moisture and light. Keep solutions cold and divide them into single-use portions.

Does the V8 product page list native IGF-1?

The page covered here is for IGF-1 LR3 in a 1 mg lyophilized format with purity stated as ≥98% by HPLC. Native IGF-1 is discussed here only as the reference molecule.

Related reading: IGF-1 LR3 Half-Life: What Published Studies Report, IGF-1 LR3 Mechanism of Action: Receptor Signaling, IGF-1 LR3 Quality Testing: A Lab Verification Guide.

References

  1. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253(8):2769-2776. doi:10.1016/S0021-9258(17)40889-1
  2. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhancing growth. J Mol Endocrinol. 1992;8(3):213-223. doi:10.1677/jme.0.0080213
  3. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. 1987;149(2):398-404. doi:10.1016/0006-291X(87)90380-9
  4. Bayne ML, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/S0021-9258(18)68777-0
  5. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976. doi:10.1152/ajpendo.2000.278.6.E967
  6. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854. doi:10.1210/er.2001-0033
  7. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. 2011;47(1):R1-R10. doi:10.1530/JME-11-0022
  8. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.